University of Virginia Patent Foundation

Other

Mark D Okusa

John Alexander Hossack

Timothy L MacDonald

Joel M Linden

Gail W Sullivan

Ian J Sarembock

Rahul Sharma

Irving L Kron

W Michael Scheld

Kevin R Lynch

Webster L Santos

Christopher E Heise

Alaa S Awad

Joseph C Gigliotti

The present application discloses a novel fusion peptide of IL-2 and IL-33 and its use. It comprises a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment or homolog thereof, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment or homolog thereof. The two portions can be linked by a linker sequence. The application discloses that combination therapies using IL-2 and IL-33 or a therapy using the IL233 fusion protein are effective in preventing or treating diseases and disorders such as autoimmune diseases and disorders, inflammation, etc. Depending on the subject's disease or disorder, the compositions of the invention are useful for preventing certain symptoms, treating the disease, and alleviating at least some of the symptoms.

Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders

Methods for treating inflammation with fusion proteins comprising interleukin-2 and interleukin-33

Fusion protein comprising interleukin-2 and interleukin-33

The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an Aadenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor.

Agonists of A2A adenosine receptors for treatment of diabetic nephropathy

The present invention provides compositions for oral administration of compounds having Aadenosine receptor agonist activity. These compositions are useful for treatment of inflammatory conditions.

[object Object]

The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i.e. LPA1, LPA2 and LPA3). More particularly the present invention is directed to LPA analogs wherein the glycerol is replaced with ethanolamine and a variety of substitutions have been linked at the second carbon atom.

Lysophosphatidic acid receptor agonists and antagonists

Compounds and methods are provided to treat inflammatory conditions with certain A adenosine receptor antagonists.

Methods and compositions for treating inflammatory response

Compounds and methods are provided to treat inflammatory conditions with certain A,adenosine receptor antagonists.

Growing community of inventors

Charlottesville, VA, United States of America

Mark D Okusa